22nd Century Group (Nasdaq: XXII) has acquired GVB Biopharma. Read the press release here
22nd Century Group, Inc. is a leading plant biotechnology company focused on technologies that alter the level of nicotine in tobacco plants and the level of cannabinoids in hemp/cannabis plants through genetic engineering, gene-editing, and modern plant breeding. Our primary mission in tobacco is to reduce the harm caused by smoking by bringing our reduced nicotine content tobacco cigarettes – containing 95% less nicotine than conventional cigarettes – to adult smokers in the U.S. and international markets. Our mission in hemp/cannabis is to develop and commercialize proprietary hemp/cannabis plants with valuable cannabinoid profiles and desirable agronomic traits.